Bioss Inc is a leading antibody developer and manufacturer with state of the art technologies.
They have developed over 11,000 primary antibodies and more than 130,000 derived products including fluorochrome conjugated antibodies.
In addition to reliable loading control and tag antibodies, their catalog includes over 1000 specific antibodies recognising proteins with phosphorylation, acetylation, or methylation modifications.
Their company promises fast delivery with strong, top quality scientific support.
Bioss Inc is located in the greater Boston area of Massachusetts, the centre of the world's largest and fastest growing biotech community.
Bioss offers over 11,000 different primary antibodies. A primary antibody is an immunoglobulin that binds specifically to a particular protein or molecule of interest for the purpose of purifying or detecting and measuring it. We offer both polyclonal and monoclonal antibodies raised in rabbit, mouse, and goat. Polyclonal antibodies are able to recognize multiple epitopes on and antigen, making them more tolerant of minor changes in the antigen sequence. Monoclonal antibodies are made to be specific to a single epitope and can provide a stable long term supply when produced by hybridomas in vitro. Our primary antibodies are also made available conjugated to various fluorescent dyes, HRP, or Biotin.
Isotype controls are primary antibodies that lack specificity to a target, however they match the class and type of the primary antibody being used. Isotype controls are used as negative controls to help distinguish nonspecific background signal from specific antibody signal. When selecting an isotype control you should match the antibody’s host species and class. If using a primary conjugated antibody, it is important to use the same conjugation for the isotype control.
To develop and manufacture top quality antibodies that accelerate biological research and discovery.
Stratech Scientific have been successful in a recent antibodies tender from the Southern Universities Purchasing Consortium. In the award criterion Read More…